Cargando…

Surrogate Prognostic Biomarkers in OSCC: The Paradigm of PA28γ Overexpression

Detalles Bibliográficos
Autor principal:	Kontos, Christos K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2015
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4563143/ https://www.ncbi.nlm.nih.gov/pubmed/26425675 http://dx.doi.org/10.1016/j.ebiom.2015.07.032

Ejemplares similares

PA28γ, an Accomplice to Malignant Cancer
por: Lei, Kexin, et al.
Publicado: (2020)

PA28γ: New Insights on an Ancient Proteasome Activator
por: Cascio, Paolo
Publicado: (2021)

FKBP51 Immunohistochemical Expression: A New Prognostic Biomarker for OSCC?
por: Russo, Daniela, et al.
Publicado: (2017)

Proteasome activators, PA28γ and PA200, play indispensable roles in male fertility
por: Huang, Lin, et al.
Publicado: (2016)

DDX59-AS1 is a prognostic biomarker and correlated with immune infiltrates in OSCC
por: Sun, Yang, et al.
Publicado: (2022)

Overexpression of proteasomal activator PA28α serves as a prognostic factor in oral squamous cell carcinoma
por: Feng, Xiaodong, et al.
Publicado: (2016)

ASCT2 overexpression is associated with poor survival of OSCC patients and ASCT2 knockdown inhibited growth of glutamine‐addicted OSCC cells
por: Luo, Yijun, et al.
Publicado: (2020)

Proteasome activator 28γ (PA28γ) allosterically activates trypsin-like proteolysis by binding to the α-ring of the 20S proteasome
por: Thomas, Taylor A., et al.
Publicado: (2022)

The Challenges of OSCC Diagnosis: Salivary Cytokines as Potential Biomarkers
por: Roi, Alexandra, et al.
Publicado: (2020)

Increased proteasome activator 28 gamma (PA28γ) levels are unspecific but correlate with disease activity in rheumatoid arthritis
por: Gruner, Melanie, et al.
Publicado: (2014)

Pulse rate variability: a new biomarker, not a surrogate for heart rate variability
por: Yuda, Emi, et al.
Publicado: (2020)

Does the biomarker search paradigm need re-booting?
por: Hurst, Robert E
Publicado: (2009)

Need for better reporting of trials with surrogate endpoints: SPIRIT|CONSORT-SURROGATE extensions
por: Ciani, Oriana, et al.
Publicado: (2022)

IFNγ signaling response in peripheral blood monocytes: A new prognostic biomarker for breast cancer?
por: Deschoemaeker, Sofie, et al.
Publicado: (2020)

Devil in the detail: MET overexpression fails as surrogate marker for MET exon 14 splice site mutations in NSCLC
por: Strickland, Matthew R., et al.
Publicado: (2020)

A Paradigm to Discover Biomarkers Associated With Chronic Kidney Disease Progression
por: Ali, Ibrahim, et al.
Publicado: (2020)

ALDH1 as a prognostic marker for lymph node metastasis in OSCC
por: Götz, Carolin, et al.
Publicado: (2018)

Proteasome activator PA28γ-dependent degradation of coronavirus disease (COVID-19) nucleocapsid protein
por: Zhang, Haiyang, et al.
Publicado: (2020)

Debate: The slippery slope of surrogate outcomes
por: D'Agostino, Ralph B
Publicado: (2000)

The Search for Surrogate Endpoints in Trials in Diffuse Large B‐Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project
por: Sargent, Daniel J., et al.
Publicado: (2017)

Proteasome Activators, PA28α and PA28β, Govern Development of Microvascular Injury in Diabetic Nephropathy and Retinopathy
por: Yadranji Aghdam, Saeed, et al.
Publicado: (2016)

Is critical care ready for an economic surrogate endpoint?
por: Wilcox, M Elizabeth, et al.
Publicado: (2015)

Surrogate strains of human pathogens for field release
por: Park, Sangjin, et al.
Publicado: (2017)

PA28αβ overexpression enhances learning and memory of female mice without inducing 20S proteasome activity
por: Adelöf, Julia, et al.
Publicado: (2018)

Proteasome activator PA28γ regulates p53 by enhancing its MDM2-mediated degradation
por: Zhang, Zhuo, et al.
Publicado: (2008)

PIP30/FAM192A is a novel regulator of the nuclear proteasome activator PA28γ
por: Jonik-Nowak, Beata, et al.
Publicado: (2018)

Paradigm Shift or Shifting Paradigm for Type 1 Diabetes
por: Nakayama, Maki, et al.
Publicado: (2012)

Expression of Radioresistant Gene PEG10 in OSCC Patients and Its Prognostic Significance
por: Singh, Shankar Sharan, et al.
Publicado: (2017)

Gene Expression in Uninvolved Oral Mucosa of OSCC Patients Facilitates Identification of Markers Predictive of OSCC Outcomes
por: Lohavanichbutr, Pawadee, et al.
Publicado: (2012)

Debate: Are surrogate end-point studies worth the effort?
por: Valabhji, Jonathan, et al.
Publicado: (2000)

Surrogate endpoints in trials: a call for better reporting
por: Ciani, Oriana, et al.
Publicado: (2022)

PA28α overexpressing female mice maintain exploratory behavior and capacity to prevent protein aggregation in hippocampus as they age
por: Adelöf, Julia, et al.
Publicado: (2021)

The CS1 segment of fibronectin is involved in human OSCC pathogenesis by mediating OSCC cell spreading, migration, and invasion
por: Kamarajan, Pachiyappan, et al.
Publicado: (2010)

The Proteasome Activator PA28γ, a Negative Regulator of p53, Is Transcriptionally Up-Regulated by p53
por: Wan, Zhen-Xing, et al.
Publicado: (2014)

Cold temperature extends longevity and prevents disease-related protein aggregation through PA28γ-induced proteasomes
por: Lee, Hyun Ju, et al.
Publicado: (2023)

Prognostic impact of mRNA levels of LGR5 transcript variants in OSCC patients
por: Rot, Swetlana, et al.
Publicado: (2019)

Surrogate endpoints and competing risk of death in cardiac arrest research
por: McCredie, Victoria A., et al.
Publicado: (2016)

Survival-Based Biomarker Module Identification Associated with Oral Squamous Cell Carcinoma (OSCC)
por: Singh, Prithvi, et al.
Publicado: (2021)

The role of proteasome activators PA28αβ and PA200 in brown adipocyte differentiation and function
por: Koçberber, Zeynep, et al.
Publicado: (2023)

PA28αβ: The Enigmatic Magic Ring of the Proteasome?
por: Cascio, Paolo
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_i2c7e5j6g0q1aetgq8pbn221dr